A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (NCT06581406)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Insisute — Scottsdale, Arizona
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- HonorHealth Research Insisute — Scottsdale, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- The Angeles Clinic and Research Institute — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
- University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) — Aurora, Colorado
- The Melanoma & Skin Cancer Institute — Englewood, Colorado
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Mayo Clinic - Jacksonville FL — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Massachusetts General Hospital — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- The Ohio State University — Columbus, Ohio
- Thomas Jefferson University — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
- University of Tennessee Medical Center — Knoxville, Tennessee
- Sarah Cannon Research Institute — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic) — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (781) 222-9570
Email: Clinicaltrials@replimune.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Uveal Melanoma
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Los Angeles, California
- Tebentafusp-tebn With LDT in Metastatic UM — Philadelphia, Pennsylvania
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma — Tampa, Florida
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma — Los Angeles, California
- Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma — Tampa, Florida
Explore by condition: All Metastatic Uveal Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.